Matrix metalloproteinase-11/stromelysin-3 exhibits collagenolytic function against collagen VI under normal and malignant conditions

Oncogene

Volumn 27, Issue 49, 2008, Pages 6347-6355

  Motrescu, E R ^a   Blaise, S ^a   Etique, N ^a   Messaddeq, N ^a   Chenard, M P ^b   Stoll, I ^a   Tomasetto, C ^a   Rio, M C ^a  

^a INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^b HÔPITAL DE HAUTEPIERRE   (France)

Author keywords

Adipocyte; Breast cancer; Collagen VI; Fat tissue; Matrix metalloproteinase 11 stromelysin 3

Indexed keywords

COLLAGEN TYPE 6; STROMELYSIN 3;

ADIPOCYTE; ADIPOGENESIS; ANIMAL CELL; ARTICLE; BREAST CARCINOMA; CELL DIFFERENTIATION; COLLAGEN DEGRADATION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FOLDING; TUMOR GROWTH;

3T3-L1 CELLS; ADIPOCYTES; ANIMALS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELLS, CULTURED; COLLAGEN; COLLAGEN TYPE VI; EMBRYO, MAMMALIAN; EXTRACELLULAR MATRIX; EXTRACELLULAR MATRIX PROTEINS; FIBROBLASTS; GLIOBLASTOMA; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MATRIX METALLOPROTEINASE 11; MICE; OSTEOSARCOMA; RECOMBINANT PROTEINS; SILVER STAINING;

EID: 54549116857     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.218     Document Type: Article

References (29)

1. Aigner T, Hambach L, Soder S, Schlotzer-Schrehardt U, Poschl E. (2002). The C5 domain of Col6A3 is cleaved off from the Col6 fibrils immediately after secretion. Biochem Biophys Res Commun 290: 743-748.
2. Andarawewa KL, Motrescu ER, Chenard MP, Gansmuller A, Stoll I, Tomasetto C et al. (2005). Stromelysin-3 is a potent negative regulator of adipogenesis participating to cancer cell-adipocyte interaction/crosstalk at the tumor invasive front. Cancer Res 65: 10862-10871.
3. Basset P, Bellocq JP, Wolf C, Stoll I, Hutin P, Limacher JM et al. (1990). A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 348: 699-704.
4. Basset P, Okada A, Chenard MP, Kannan R, Stoll I, Anglard P et al. (1997). Matrix metalloproteinases as stromal effectors of human carcinoma progression: therapeutic implications. Matrix Biol 15: 535-541.
5. Bernlohr DA, Angus CW, Lane MD, Bolanowski MA, Kelly Jr TJ. (1984). Expression of specific mRNAs during adipose differentiation: identification of an mRNA encoding a homologue of myelin P2 protein. Proc Natl Acad Sci USA 81: 5468-5472.
6. Boulay A, Masson R, Chenard MP, El Fahime M, Cassard L, Bellocq JP et al. (2001). High cancer cell death in syngeneic tumors developed in host mice deficient for the stromelysin-3 matrix metalloproteinase. Cancer Res 61: 2189-2193.
7. Celis JE, Moreira JM, Cabezon T, Gromov P, Friis E, Rank F et al. (2005). Identification of extracellular and intracellular signaling components of the mammary adipose tissue and its interstitial fluid in high risk breast cancer patients: toward dissecting the molecular circuitry of epithelial-adipocyte stromal cell interactions. Mol Cell Proteomics 4: 492-522.
8. Dieudonne MN, Bussiere M, Dos Santos E, Leneveu MC, Giudicelli Y, Pecquery R. (2006). Adiponectin mediates antiproliferative and apoptotic responses in human MCF7 breast cancer cells. Biochem Biophys Res Commun 345: 271-279.
9. Gregoire FM. (2001). Adipocyte differentiation: from fibroblast to endocrine cell. Exp Biol Med (Maywood) 226: 997-1002.
10. Han J, Daniel JC. (1995). Biosynthesis of type VI collagen by glioblastoma cells and possible function in cell invasion of three-dimensional matrices. Connect Tissue Res 31: 161-170.
11. Iyengar P, Combs TP, Shah SJ, Gouon-Evans V, Pollard JW, Albanese C et al. (2003). Adipocyte-secreted factors synergistically promote mammary tumorigenesis through induction of anti-apoptotic transcriptional programs and proto-oncogene stabilization. Oncogene 22: 6408-6423.
12. Iyengar P, Espina V, Williams TW, Lin Y, Berry D, Jelicks LA et al. (2005). Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment. J Clin Invest 115: 1163-1176.
13. Kannan R, Ruff M, Kochins JG, Manly SP, Stoll I, El Fahime M et al. (1999). Purification of active matrix metalloproteinase catalytic domains and its use for screening of specific stromelysin-3 inhibitors. Protein Expr Purif 16: 76-83.
14. Kielty CM, Lees M, Shuttleworth CA, Woolley D. (1993). Catabolism of intact type VI collagen microfibrils: susceptibility to degradation by serine proteinases. Biochem Biophys Res Commun 191: 1230-1236.
15. Kuo HJ, Maslen CL, Keene DR, Glanville RW. (1997). Type VI collagen anchors endothelial basement membranes by interacting with type IV collagen. J Biol Chem 272: 26522-26529.
16. Lamande SR, Morgelin M, Adams NE, Selan C, Allen JM. (2006). The C5 domain of the collagen VI alpha3(VI) chain is critical for extracellular microfibril formation and is present in the extracellular matrix of cultured cells. J Biol Chem 281: 16607-16614.
17. Manabe Y, Toda S, Miyazaki K, Sugihara H. (2003). Mature adipocytes, but not preadipocytes, promote the growth of breast carcinoma cells in collagen gel matrix culture through cancer-stromal cell interactions. J Pathol 201: 221-228.
18. Masson R, Lefebvre O, Noel A, Fahime ME, Chenard MP, Wendling C et al. (1998). In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy. J Cell Biol 140: 1535-1541.
19. McCawley LJ, Matrisian LM. (2001). Matrix metalloproteinases: they're not just for matrix anymore. Curr Opin Cell Biol 13: 534-540.
20. Motrescu ER, Rio MC. (2008). Cancer cells, adipocytes and matrix metalloproteinase 11: a vicious tumor progression cycle. Biol Chem 389.
21. Myint E, Brown DJ, Ljubimov AV, Kyaw M, Kenney MC. (1996). Cleavage of human corneal type VI collagen alpha 3 chain by matrix metalloproteinase-2. Cornea 15: 490-496.
22. Nakajima I, Muroya S, Tanabe R, Chikuni K. (2002). Positive effect of collagen V and VI on triglyceride accumulation during differentiation in cultures of bovine intramuscular adipocytes. Differentiation 70: 84-91.
23. Noel A, Boulay A, Kebers F, Kannan R, Hajitou A, Calberg-Bacq CM et al. (2000). Demonstration in vivo that stromelysin-3 functions through its proteolytic activity. Oncogene 19: 1605-1612.
24. Noel A, Santavicca M, Stoll I, L'Hoir C, Staub A, Murphy G et al. (1995). Identification of structural determinants controlling human and mouse stromelysin-3 proteolytic activities. J Biol Chem 270: 22866-22872.
25. Pei D, Majmudar G, Weiss SJ. (1994). Hydrolytic inactivation of a breast carcinoma cell-derived serpin by human stromelysin-3. J Biol Chem 269: 25849-25855.
26. Pei D, Weiss SJ. (1995). Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature 375: 244-247.
27. Rio MC. (2002). Stromelysin-3, a Particular Member of the Matrix Metalloproteinase Family, kluwer academic edn. Kluwer Academic Publisher: Dordrecht.
28. Ruhl M, Johannsen M, Atkinson J, Manski D, Sahin E, Somasundaram R et al. (1999). Soluble collagen VI induces tyrosine phosphorylation of paxillin and focal adhesion kinase and activates the MAP kinase erk2 in fibroblasts. Exp Cell Res 250: 548-557.
29. Schaffler A, Scholmerich J, Buechler C. (2007). Mechanisms of disease: adipokines and breast cancer - endocrine and paracrine mechanisms that connect adiposity and breast cancer. Nat Clin Pract Endocrinol Metab 3: 345-354.